nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—SSTR2—SIDS Susceptibility Pathways—FMO3—metabolic syndrome X	0.0371	0.0371	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—FMO3—metabolic syndrome X	0.0292	0.0292	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Other—CNR1—metabolic syndrome X	0.021	0.021	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—PLA2G6—metabolic syndrome X	0.0203	0.0203	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—GCK—metabolic syndrome X	0.0169	0.0169	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—MTNR1B—metabolic syndrome X	0.0152	0.0152	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—MTNR1B—metabolic syndrome X	0.0141	0.0141	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—MTNR1B—metabolic syndrome X	0.0141	0.0141	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—GCK—metabolic syndrome X	0.0133	0.0133	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—GHRL—metabolic syndrome X	0.0133	0.0133	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—MTNR1B—metabolic syndrome X	0.013	0.013	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—GHRL—metabolic syndrome X	0.0123	0.0123	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—MTNR1B—metabolic syndrome X	0.0121	0.0121	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—metabolic syndrome X	0.0112	0.0112	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—HTR2C—metabolic syndrome X	0.011	0.011	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CNR1—metabolic syndrome X	0.0107	0.0107	CbGpPWpGaD
Vapreotide—TACR1—G alpha (q) signalling events—HTR2C—metabolic syndrome X	0.0104	0.0104	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—HTR2C—metabolic syndrome X	0.0102	0.0102	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—CNR1—metabolic syndrome X	0.00989	0.00989	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CNR1—metabolic syndrome X	0.00983	0.00983	CbGpPWpGaD
Vapreotide—TACR1—G alpha (q) signalling events—GHRL—metabolic syndrome X	0.00981	0.00981	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL5—metabolic syndrome X	0.00979	0.00979	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—NR3C1—metabolic syndrome X	0.00975	0.00975	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—GHRL—metabolic syndrome X	0.00969	0.00969	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—HTR2C—metabolic syndrome X	0.00944	0.00944	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—metabolic syndrome X	0.00926	0.00926	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—MTNR1B—metabolic syndrome X	0.00922	0.00922	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—CNR1—metabolic syndrome X	0.00912	0.00912	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL5—metabolic syndrome X	0.00903	0.00903	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—GHRL—metabolic syndrome X	0.00894	0.00894	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—metabolic syndrome X	0.0088	0.0088	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—metabolic syndrome X	0.00878	0.00878	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—HTR2C—metabolic syndrome X	0.00871	0.00871	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—LEP—metabolic syndrome X	0.00853	0.00853	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—MTNR1B—metabolic syndrome X	0.00851	0.00851	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CNR1—metabolic syndrome X	0.00847	0.00847	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CCL5—metabolic syndrome X	0.00826	0.00826	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—GHRL—metabolic syndrome X	0.00825	0.00825	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—AGT—metabolic syndrome X	0.00819	0.00819	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CNR1—metabolic syndrome X	0.00782	0.00782	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—NR3C1—metabolic syndrome X	0.00768	0.00768	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CCL5—metabolic syndrome X	0.00762	0.00762	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—AGT—metabolic syndrome X	0.00756	0.00756	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—HTR2C—metabolic syndrome X	0.00719	0.00719	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—CCL2—metabolic syndrome X	0.00717	0.00717	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL5—metabolic syndrome X	0.00711	0.00711	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—AGT—metabolic syndrome X	0.00691	0.00691	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2C—metabolic syndrome X	0.00686	0.00686	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—GHRL—metabolic syndrome X	0.00681	0.00681	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CCL2—metabolic syndrome X	0.00674	0.00674	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—MTNR1B—metabolic syndrome X	0.0067	0.0067	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—HTR2C—metabolic syndrome X	0.00663	0.00663	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL5—metabolic syndrome X	0.00657	0.00657	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—GHRL—metabolic syndrome X	0.0065	0.0065	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CNR1—metabolic syndrome X	0.00645	0.00645	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—AGT—metabolic syndrome X	0.00637	0.00637	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—GHRL—metabolic syndrome X	0.00629	0.00629	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CCL2—metabolic syndrome X	0.00622	0.00622	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CNR1—metabolic syndrome X	0.00615	0.00615	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL5—metabolic syndrome X	0.00606	0.00606	CbGpPWpGaD
Vapreotide—TACR1—G alpha (q) signalling events—AGT—metabolic syndrome X	0.00603	0.00603	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CNR1—metabolic syndrome X	0.00595	0.00595	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—AGT—metabolic syndrome X	0.00595	0.00595	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—PTGS2—metabolic syndrome X	0.00585	0.00585	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—AGT—metabolic syndrome X	0.00549	0.00549	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—metabolic syndrome X	0.00539	0.00539	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—HTR2C—metabolic syndrome X	0.00522	0.00522	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—MTNR1B—metabolic syndrome X	0.00521	0.00521	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—AGT—metabolic syndrome X	0.00507	0.00507	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL5—metabolic syndrome X	0.005	0.005	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—GHRL—metabolic syndrome X	0.00495	0.00495	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CCL2—metabolic syndrome X	0.0049	0.0049	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—MTNR1B—metabolic syndrome X	0.00481	0.00481	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL5—metabolic syndrome X	0.00477	0.00477	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—MTNR1B—metabolic syndrome X	0.00473	0.00473	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CNR1—metabolic syndrome X	0.00469	0.00469	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL5—metabolic syndrome X	0.00461	0.00461	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	0.00452	0.00452	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—MTNR1B—metabolic syndrome X	0.00437	0.00437	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TGFB1—metabolic syndrome X	0.00423	0.00423	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—AGT—metabolic syndrome X	0.00418	0.00418	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	0.00417	0.00417	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—HTR2C—metabolic syndrome X	0.00406	0.00406	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—TNF—metabolic syndrome X	0.00401	0.00401	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—AGT—metabolic syndrome X	0.00399	0.00399	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TNF—metabolic syndrome X	0.00395	0.00395	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—AGT—metabolic syndrome X	0.00386	0.00386	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—GHRL—metabolic syndrome X	0.00385	0.00385	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—MTNR1B—metabolic syndrome X	0.00379	0.00379	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—HTR2C—metabolic syndrome X	0.00375	0.00375	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—HTR2C—metabolic syndrome X	0.00369	0.00369	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CNR1—metabolic syndrome X	0.00365	0.00365	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL5—metabolic syndrome X	0.00363	0.00363	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—GHRL—metabolic syndrome X	0.00355	0.00355	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—GHRL—metabolic syndrome X	0.0035	0.0035	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CCL2—metabolic syndrome X	0.00344	0.00344	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—MTNR1B—metabolic syndrome X	0.00344	0.00344	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—HTR2C—metabolic syndrome X	0.0034	0.0034	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CNR1—metabolic syndrome X	0.00336	0.00336	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CNR1—metabolic syndrome X	0.00331	0.00331	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—metabolic syndrome X	0.00329	0.00329	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL6—metabolic syndrome X	0.00324	0.00324	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—GHRL—metabolic syndrome X	0.00323	0.00323	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL6—metabolic syndrome X	0.00319	0.00319	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CCL2—metabolic syndrome X	0.00318	0.00318	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—TNF—metabolic syndrome X	0.00316	0.00316	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—HDAC3—metabolic syndrome X	0.00313	0.00313	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CNR1—metabolic syndrome X	0.00305	0.00305	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—AGT—metabolic syndrome X	0.00304	0.00304	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—HTR2C—metabolic syndrome X	0.00295	0.00295	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—HDAC3—metabolic syndrome X	0.00289	0.00289	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CCL5—metabolic syndrome X	0.00283	0.00283	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—GHRL—metabolic syndrome X	0.0028	0.0028	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—MTNR1B—metabolic syndrome X	0.0028	0.0028	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TRIB3—metabolic syndrome X	0.00272	0.00272	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—RBP4—metabolic syndrome X	0.00272	0.00272	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—HTR2C—metabolic syndrome X	0.00268	0.00268	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CNR1—metabolic syndrome X	0.00265	0.00265	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CCL5—metabolic syndrome X	0.00261	0.00261	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—MTNR1B—metabolic syndrome X	0.00258	0.00258	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL5—metabolic syndrome X	0.00257	0.00257	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—PLA2G4A—metabolic syndrome X	0.00256	0.00256	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL6—metabolic syndrome X	0.00255	0.00255	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—GHRL—metabolic syndrome X	0.00254	0.00254	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TRIB3—metabolic syndrome X	0.00251	0.00251	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—RBP4—metabolic syndrome X	0.00251	0.00251	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CCL2—metabolic syndrome X	0.0025	0.0025	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—APOC3—metabolic syndrome X	0.00241	0.00241	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CNR1—metabolic syndrome X	0.00241	0.00241	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL5—metabolic syndrome X	0.00237	0.00237	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—AGT—metabolic syndrome X	0.00236	0.00236	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—PLA2G4A—metabolic syndrome X	0.00236	0.00236	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—HDAC3—metabolic syndrome X	0.00227	0.00227	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—APOC3—metabolic syndrome X	0.00223	0.00223	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—AGT—metabolic syndrome X	0.00218	0.00218	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—HTR2C—metabolic syndrome X	0.00218	0.00218	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—AGT—metabolic syndrome X	0.00215	0.00215	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CYBA—metabolic syndrome X	0.00211	0.00211	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GHRL—metabolic syndrome X	0.00206	0.00206	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CCL5—metabolic syndrome X	0.00205	0.00205	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—MTNR1B—metabolic syndrome X	0.00203	0.00203	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—HTR2C—metabolic syndrome X	0.00201	0.00201	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—AGT—metabolic syndrome X	0.00198	0.00198	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TRIB3—metabolic syndrome X	0.00198	0.00198	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—RBP4—metabolic syndrome X	0.00198	0.00198	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—metabolic syndrome X	0.00197	0.00197	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CNR1—metabolic syndrome X	0.00196	0.00196	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CYBA—metabolic syndrome X	0.00195	0.00195	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GHRL—metabolic syndrome X	0.00191	0.00191	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL5—metabolic syndrome X	0.00186	0.00186	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PLA2G4A—metabolic syndrome X	0.00186	0.00186	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CNR1—metabolic syndrome X	0.0018	0.0018	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CCL2—metabolic syndrome X	0.00177	0.00177	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—APOC3—metabolic syndrome X	0.00175	0.00175	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—AGT—metabolic syndrome X	0.00172	0.00172	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CCL2—metabolic syndrome X	0.00163	0.00163	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IGF2—metabolic syndrome X	0.0016	0.0016	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—HTR2C—metabolic syndrome X	0.00158	0.00158	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—AGT—metabolic syndrome X	0.00156	0.00156	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—APOB—metabolic syndrome X	0.00155	0.00155	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CYBA—metabolic syndrome X	0.00153	0.00153	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL5—metabolic syndrome X	0.00152	0.00152	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PLA2G4A—metabolic syndrome X	0.00151	0.00151	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GHRL—metabolic syndrome X	0.0015	0.0015	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—LPL—metabolic syndrome X	0.00148	0.00148	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IGF2—metabolic syndrome X	0.00148	0.00148	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—APOB—metabolic syndrome X	0.00143	0.00143	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CNR1—metabolic syndrome X	0.00142	0.00142	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL5—metabolic syndrome X	0.0014	0.0014	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PLA2G4A—metabolic syndrome X	0.00139	0.00139	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—LPL—metabolic syndrome X	0.00137	0.00137	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CCL2—metabolic syndrome X	0.00128	0.00128	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—AGT—metabolic syndrome X	0.00127	0.00127	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—LEP—metabolic syndrome X	0.00124	0.00124	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—APOE—metabolic syndrome X	0.00124	0.00124	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—APOA1—metabolic syndrome X	0.00123	0.00123	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—AGT—metabolic syndrome X	0.00117	0.00117	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IGF2—metabolic syndrome X	0.00116	0.00116	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—LEP—metabolic syndrome X	0.00115	0.00115	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—APOE—metabolic syndrome X	0.00115	0.00115	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—APOA1—metabolic syndrome X	0.00113	0.00113	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—APOB—metabolic syndrome X	0.00113	0.00113	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IRS1—metabolic syndrome X	0.00111	0.00111	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL5—metabolic syndrome X	0.0011	0.0011	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PLA2G4A—metabolic syndrome X	0.0011	0.0011	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—LPL—metabolic syndrome X	0.00108	0.00108	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—INS—metabolic syndrome X	0.00106	0.00106	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CCL2—metabolic syndrome X	0.00104	0.00104	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IGF1—metabolic syndrome X	0.00103	0.00103	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IRS1—metabolic syndrome X	0.00102	0.00102	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—INS—metabolic syndrome X	0.000979	0.000979	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SERPINE1—metabolic syndrome X	0.000975	0.000975	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CCL2—metabolic syndrome X	0.000964	0.000964	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IGF1—metabolic syndrome X	0.000947	0.000947	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NOS3—metabolic syndrome X	0.000931	0.000931	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—AGT—metabolic syndrome X	0.000921	0.000921	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—LEP—metabolic syndrome X	0.000903	0.000903	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—APOE—metabolic syndrome X	0.000903	0.000903	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SERPINE1—metabolic syndrome X	0.0009	0.0009	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—APOA1—metabolic syndrome X	0.000892	0.000892	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NOS3—metabolic syndrome X	0.000859	0.000859	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IRS1—metabolic syndrome X	0.000805	0.000805	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—AKT1—metabolic syndrome X	0.000797	0.000797	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—IL6—metabolic syndrome X	0.000785	0.000785	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—INS—metabolic syndrome X	0.000771	0.000771	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CCL2—metabolic syndrome X	0.000759	0.000759	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IGF1—metabolic syndrome X	0.000746	0.000746	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—AKT1—metabolic syndrome X	0.000736	0.000736	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—IL6—metabolic syndrome X	0.000724	0.000724	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—AKT1—metabolic syndrome X	0.000724	0.000724	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SERPINE1—metabolic syndrome X	0.000708	0.000708	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NOS3—metabolic syndrome X	0.000676	0.000676	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—AKT1—metabolic syndrome X	0.000668	0.000668	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TGFB1—metabolic syndrome X	0.000615	0.000615	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—AKT1—metabolic syndrome X	0.000579	0.000579	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—IL6—metabolic syndrome X	0.00057	0.00057	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TGFB1—metabolic syndrome X	0.000568	0.000568	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—AKT1—metabolic syndrome X	0.000526	0.000526	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IL6—metabolic syndrome X	0.000464	0.000464	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TGFB1—metabolic syndrome X	0.000447	0.000447	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IL6—metabolic syndrome X	0.000428	0.000428	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—AKT1—metabolic syndrome X	0.000428	0.000428	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—AKT1—metabolic syndrome X	0.000395	0.000395	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IL6—metabolic syndrome X	0.000337	0.000337	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—AKT1—metabolic syndrome X	0.000311	0.000311	CbGpPWpGaD
